HPSC BioSeed · Regenerative Medicine

The Future of Medicine is Cellular

Pioneering placental mesenchymal stem cell and exosome technology. Received the Investigational New Drug (IND) approval from the U.S. FDA (NCT05886985) and has entered the clinical stage: https://clinicaltrials.gov/study/NCT05886985

Explore Our Science
HPSC Platform

16+

Preclinical Studies

US FDA

IND Authorization

2006

Research Since

29+

Patents Applied

chemist, laboratory, analysis, chemistry, research, woman, female, girl, laboratory, laboratory, laboratory, laboratory, laboratory, chemistry, chemistry, research, research
Electrifying plasma ball emitting vivid purple arcs against a dark background.

What We Do

Transforming Regenerative Medicine

“If the 20th century was the era of drug therapy, the 21st century will be the era of cell therapy.” — George Daley, Dean, Harvard Medical School
Placental Stem Cells
Proprietary isolation of placental mesenchymal stem cells (pcMSC) with superior immunomodulatory and regenerative capabilities — non-invasively sourced and age-independent.
World-first functional exosome platform with Japanese patent secured and US patent pending. Nano-scale vesicles capable of crossing the blood-brain barrier for CNS applications.
Registered product under FDA IND approval — one of only two globally authorized placental cell drug programs. Now in human clinical study stages.

Scientific Edge

Why Placental Stem Cells?

Most global cell technology programs rely on umbilical cord or adipose-derived stem cells. Placental mesenchymal stem cells are far more potent — but vastly more difficult to isolate and standardize.

We solved both challenges. Our proprietary single-cell purification and serum-free culture technology produces pharmaceutical-grade placental stem cells at scale.

  • Non-invasive, ethically sourced placental tissue
  • Minimal age-related decline in potency
  • Powerful dual-effect: regeneration + immune modulation
  • Non-tumorigenic verified — proven safe for clinical use
  • Quantifiable, scalable GMP-grade production
pcMSC vs Other MSC Sources — Differentiation Potential
pcMSC (Placental)
Superior ★
UC-MSC (Umbilical)
Good
ADSC (Adipose)
Moderate
BMSC (Bone Marrow)
Moderate
Key Advantages of pcMSC
25th Sub-generations
0% Tumorigenic
GMP Grade Certified
Safety Evidence

Non-Tumorigenic Profile

Published data comparing cancer promotion risks across different mesenchymal stem cell sources confirms that placental pcMSC does not promote tumour growth — a critical safety threshold for clinical application.

Milestones

Our Journey

2006
HPSC+ Program Founded

Launched the Human Pluripotent Stem Cell research program with collaboration from National Taiwan University, Taipei Medical University, and Academia Sinica.

2013
Nobel Prize Validation

James E. Rothman received the Nobel Prize in Physiology or Medicine for discoveries related to cellular vesicle transport — foundational to exosome science.

2023
Compassionate Use Success & Science Publication

HPSC demonstrated significant therapeutic effects in compassionate use cases. Published in Frontiers in Immunology. Clinical trial registered: NCT05886985.

2023
FDA IND Authorization

Received US FDA Investigational New Drug approval — one of only two placental cell technology programs globally to achieve this milestone. Entered human clinical stage.

2024
Japan Exosome Patent Granted

World's first functional exosome technology patent secured in Japan. US patent application in progress. Asia-Pacific Bioprocessing Excellence Award received.

2025
Biospring X (M) Sdn Bhd Incorporated · 2026 Expansion

Malaysian entity (Reg. 202501004960) established in Kuala Lumpur in February 2025, expanding our presence in Southeast Asia under the HPSC BioSeed brand. Further regional growth planned for 2026.

Contemporary skyscraper set against a vibrant sky in Pretoria, South Africa.
Global Collaboration

Research Partners

We collaborate with internationally recognized academic and medical institutions across Taiwan.

  • 🎓 University of California, Davis (UC Davis)
  • 🎓 National Taiwan University
  • 🎓 Taipei Medical University
  • 🎓 Academia Sinica
  • 🏭 Industrial Technology Research Institute
  • 🌐 800+ Participating Institutions
  • 👨‍🔬 130+ Master's and doctoral degree holders in stem cell-related academics, research, clinical practice, production, and management

Recognition

Research & Development Awards

Research & Development Award — Official Award Wall, Biospring Medical Co., Ltd.
Scroll to Top